While disappointed by the miss on Sesen's ability to execute an independent commercial launch of vicineum for bladder cancer, based on the facts and the financial market conditions last year, I think the transaction provides the best value for me and a good shot on goal with Carisma validated with the cash of the other pharma/investor players they attracted.
News 
Market Data 
Discover 
